80,550 results match your criteria Parkinsonism & Related Disorders [Journal]


A double blind randomized controlled trial to assess efficacy of bromocriptine in cirrhotic patients with hepatic parkinsonism.

Liver Int 2018 Dec 16. Epub 2018 Dec 16.

Departments of Hepatology, Institute of Liver and Biliary Sciences, New Delhi, India.

Background: Parkinsonism like features can be seen in cirrhotics, possibly related to alterations in brain dopamine metabolism, transport and receptor integrity at basal ganglia. Hepatic parkinsonism [HP] is often not suspected and only ammonia reducing therapies are given to such patients. We investigated the efficacy and safety of bromocriptine, a dopaminergic agent, in patients with HP. Read More

View Article
December 2018

Differential accumulation of Tau phosphorylated at residues Thr231, Ser262 and Thr205 in hippocampal interneurons and its modulation by Tau mutations (VLW) and amyloid-β peptide.

Neurobiol Dis 2018 Dec 13. Epub 2018 Dec 13.

Department of Cell Biology, Physiology and Immunology, Institut de Neurociències, Universitat de Barcelona, Barcelona, Spain; Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED, ISCIII), Spain; Vall d'Hebron Institute of Research, Barcelona, Spain. Electronic address:

Alzheimer's disease (AD) is characterized by the accumulation of amyloid-β peptide (Aβ) and hyperphosphorylated Tau protein (P-Tau). Our recent data showed a differential accumulation of Tau protein phosphorylated at Thr231 in distinct hippocampal neurons in VLW mice-an animal model that overexpresses mutated human Tau. Here we demonstrate that, in VLW mice, the accumulation of human P-Tau in the pyramidal cells induces the phosphorylation of murine Tau at Thr231 (pThr231) in hippocampal interneurons. Read More

View Article
December 2018

Deep brain stimulation of the subthalamic nucleus in Parkinson's disease: Relationship between the electrode trajectory and cognitive decline.

Parkinsonism Relat Disord 2018 Dec 8. Epub 2018 Dec 8.

Department of Psychology, University of Turin, Via Verdi, 8 - 10124, Turin, Italy.

Introduction: It remains to be clarified whether penetration of the caudate nucleus increases the risk of cognitive decline in patients with Parkinson's disease (PD) undergoing deep brain stimulation (DBS) of the subthalamic nucleus (STN).

Methods: A retrospective analysis of pre/postoperative neuropsychological changes was performed with 46 consecutive patients with PD who underwent DBS of the STN. In particular, to evaluate the possible relationship between cognitive changes and DBS lead trajectories, repeated-measures ANCOVAs were conducted to analyze the effects of group (23 patients with vs 23 patients without penetration of the caudate nucleus) and time (T0 vs T1) for each neuropsychological test. Read More

View Article
December 2018

Sensory trick efficacy in cervical dystonia is linked to processing of neck proprioception.

Parkinsonism Relat Disord 2018 Dec 5. Epub 2018 Dec 5.

Sobell Department of Motor Neuroscience and Movement Disorders, UCL Institute of Neurology, Queen Square, London, UK.

Background: Muscle vibration activates muscle spindles and when applied over posterior neck muscles during stance modulates global body orientation. This is characterised by a tonic forward sway response that is reportedly diminished or absent in patients with idiopathic cervical dystonia.

Objective: To investigating the impact of the sensory trick on vibration-induced postural responses. Read More

View Article
December 2018

Altered structural connectivity of the motor subnetwork in multiple system atrophy with cerebellar features.

Eur Radiol 2018 Dec 14. Epub 2018 Dec 14.

Symbiosis Center for Medical Image Analysis and Symbiosis Institute of Technology, Symbiosis International University, Lavale, Mulshi, Pune, Maharashtra, 412115, India.

Objectives: To investigate the structural connectivity of the motor subnetwork in multiple system atrophy with cerebellar features (MSA-C), a distinct subtype of MSA, characterized by predominant cerebellar symptoms.

Methods: Twenty-three patients with MSA-C and 25 age- and gender-matched healthy controls were recruited for the study. Disease severity was quantified using the Unified Multiple System Atrophy Rating Scale (UMSARS). Read More

View Article
December 2018
1 Read

Phase-dependent suppression of beta oscillations in Parkinson's disease patients.

J Neurosci 2018 Dec 14. Epub 2018 Dec 14.

MRC Brain Network Dynamics Unit, Department of Pharmacology, University of Oxford, Oxford OX1 3TH, United Kingdom

Synchronized oscillations within and between brain areas facilitate normal processing, but are often amplified in disease. A prominent example is the abnormally sustained beta-frequency (∼20Hz) oscillations recorded from the cortex and subthalamic nucleus of Parkinson's disease patients. Computational modelling suggests that the amplitude of such oscillations could be modulated by applying stimulation at a specific phase. Read More

View Article
December 2018

Cell Biology and Dynamics of Neuronal Na/K-ATPase in Health and Diseases.

Neuropharmacology 2018 Dec 11. Epub 2018 Dec 11.

CNRS Neurodegenerative Diseases Laboratory (UMR9199), MiRCen, CEA Fontenay-aux-Roses, 18 route du Panorama, 92265, France.

Neuronal Na/K-ATPase is responsible for the maintenance of ionic gradient across plasma membrane. In doing so, in a healthy brain, Na/K-ATPase activity accounts for nearly half of total brain energy consumption. The α3-subunit containing Na/K-ATPase expression is restricted to neurons. Read More

View Article
December 2018

Phenotypic variability and neuropsychological findings associated with C9orf72 repeat expansions in a Bulgarian dementia cohort.

PLoS One 2018 14;13(12):e0208383. Epub 2018 Dec 14.

Karolinska Institutet, Dept NVS, Division for Neurogeriatrics, Bioclinicum, Akademiska stråket, Solna, Sweden.

Background: The GGGGCC repeat expansion in the C9orf72 gene was recently identified as a major cause of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) in several European populations. The objective of this study was to determine the frequency of C9orf72 repeat expansions in a Bulgarian dementia cohort and to delineate the associated clinical features.

Methods And Findings: PCR-based assessments of the C9orf72 hexanucleotide repeat expansion in all study samples (including 82 FTD, 37 Alzheimer's disease (AD), and 16 other neurodegenerative/dementia disorder cases) were performed. Read More

View Article
December 2018

Anesthesia in Patients With Multiple-System Atrophy: A Narrative Review and Practice Guidance.

A A Pract 2018 Dec 13. Epub 2018 Dec 13.

Department of Anesthesiology and Pain Management, University of Texas Southwestern Medical Center, Dallas, Texas.

Multiple-system atrophy, a rare adult-onset neurodegenerative disease, is associated with autonomic dysfunction, features of parkinsonism, and cerebellar ataxia. This article discusses multiple-system atrophy pathophysiology, clinical presentation, and perioperative issues pertinent to anesthesia. Read More

View Article
December 2018

Cyanobacterial Neurotoxin Beta-Methyl-Amino-l-Alanine Affects Dopaminergic Neurons in Optic Ganglia and Brain of .

Toxins (Basel) 2018 Dec 8;10(12). Epub 2018 Dec 8.

Department of Zoology, Functional Morphology, Stockholm University, Svante Arrhenius väg 18B, S-10691 Stockholm, Sweden.

The non-proteinogenic amino acid beta-methyl-amino-l-alanine (BMAA) is a neurotoxin produced by cyanobacteria. BMAA accumulation in the brain of animals via biomagnification along the food web can contribute to the development of neurodegenerative diseases such as Amyotrophic lateral sclerosis/Parkinsonism dementia complex (ALS/PDC), the latter being associated with a loss of dopaminergic neurons. is an important microcrustacean zooplankton species that plays a key role in aquatic food webs, and BMAA-producing cyanobacteria often form part of their diet. Read More

View Article
December 2018

Assessment of Incidence and Character of Neurologic/ Neuropsychiatric Complications in a Group of Patients with Malignant Melanoma Treated with Adjuvant High Dose Interferon.

Klin Onkol 2018 ;31(5):361-365

Background: Authors describe the incidence and character of neurologic and neuropsychiatric complications - particularly depression and parkinsonism - during adjuvant treatment of malignant melanoma (MM) with high dose interferon (HDI). Among the most frequently observed side effects are fatigue, hematotoxicity, and hepatotoxicity. Most research has been directed at depression and parkinsonism because of the lack of literature concerning these complications. Read More

View Article
January 2018

Orexin-A Exerts Neuroprotective Effects via OX1R in Parkinson's Disease.

Front Neurosci 2018 15;12:835. Epub 2018 Nov 15.

Department of Physiology, Shandong Provincial Key Laboratory of Pathogenesis and Prevention of Neurological Disorders, Qingdao University, Qingdao, China.

Parkinson's disease (PD) is a common neurodegenerative disorder characterized by progressive and selective death of dopaminergic neurons. Orexin-A is involved in many biological effects of the body. It has been reported that orexin-A has protective effects in cellular models of PD. Read More

View Article
November 2018

Early- and late-phase F-FP-CIT PET images in vascular parkinsonism due to midbrain infarct.

Neurol Sci 2018 Dec 7. Epub 2018 Dec 7.

Department of Neurology, Dongtan Sacred Heart Hospital, College of Medicine, Hallym University, 7, Keunjaebong-gil, Hwaseong, Gyeonggi-do, 18450, Republic of Korea.

View Article
December 2018

Tardive dyskinesia: Who gets it and why.

Authors:
Karen Frei

Parkinsonism Relat Disord 2018 Nov 15. Epub 2018 Nov 15.

Loma Linda University, Loma Linda, CA, USA. Electronic address:

Tardive dyskinesia (TD) is a potentially permanent movement disorder resulting from chronic use of dopamine receptor blocking agents (DRBA). Identified risk factors include the type of antipsychotic agent, being greater for those of first generation antipsychotics (FGA), the duration of illness and cumulative dose of DRBA and advanced age. Female sex and African and Caucasian ethnicity are additional potential risk factors. Read More

View Article
November 2018
1 Read

The movement disorder spectrum of SCA21 (ATX-TMEM240): 3 novel families and systematic review of the literature.

Parkinsonism Relat Disord 2018 Nov 29. Epub 2018 Nov 29.

Department of Neurodegenerative Diseases, Hertie-Institute for Clinical Brain Research and Center of Neurology, University of Tübingen, Tübingen, Germany; German Center for Neurodegenerative Diseases (DZNE), University of Tübingen, Tübingen, Germany. Electronic address:

Spinocerebellar ataxia type 21 (SCA21/ATX-TMEM240) was recently found to be caused by mutations in TMEM240, with still limited knowledge on the phenotypic spectrum and disease course. Here we present five subjects from three novel SCA21 families from different parts of the world (including a novel c.196G > A, p. Read More

View Article
November 2018

Non-motor Symptoms in Patients with Parkinson's Disease: A Cross-sectional Survey.

Cureus 2018 Oct 4;10(10):e3412. Epub 2018 Oct 4.

Neurology, Shifa International Hospital, Islamabad, PAK.

Background In multiple studies around the globe, non-motor symptoms (NMS) have been identified as a source of immense disability in patients with Parkinson's disease (PD). However, there is a scarcity of data from Asia. This is the first study of the Pakistani population to assess the impact of NMS in PD on patients. Read More

View Article
October 2018
1 Read

Gait festination in parkinsonism: introduction of two phenotypes.

J Neurol 2018 Dec 7. Epub 2018 Dec 7.

Department of Neurology, Centre of Clinical Neuroscience, First Faculty of Medicine, General University Hospital, Charles University, Prague, Czech Republic.

Gait festination is one of the most characteristic gait disturbances in patients with Parkinson's disease or atypical parkinsonism. Although festination is common and disabling, it has received little attention in the literature, and different definitions exist. Here, we argue that there are actually two phenotypes of festination. Read More

View Article
December 2018
2 Reads

Diagnostic Utility of [11C]DTBZ Positron Emission Tomography In Clinically Uncertain Parkinsonism: Experience of a Single Tertiary Center.

Rev Invest Clin 2018 ;70(6):285-290

Movement Disorders Clinic. Instituto Nacional de Neurología y Neurocirugía, Mexico City, Mexico.

Background: The use of single-photon emission computed tomography and positron emission tomography (PET) has proven to be helpful in differentiating Parkinson's disease (PD) from other movement disorders with a sensitivity of up to 95%.

Objective: The objective of this study was to determine the accuracy of [11C]DTBZ PET imaging in patients with clinically uncertain parkinsonism from a tertiary referral center in Mexico City.

Materials And Methods: Patients who underwent [11C]DTBZ PET brain scan due to clinically uncertain parkinsonism where divided into two groups: PD or non-PD. Read More

View Article
January 2018

[Breve recorrido histórico de la enfermedad de Parkinson a 200 años de su descripción].

Gac Med Mex 2018 ;154(6):719-726

Laboratorio Clínico de Enfermedades Neurodegenerativas. Secretaría de Salud, Instituto Nacional de Neurología y Neurocirugía, Ciudad de México, México.

The original description of what currently is known as Parkinson's disease was published 200 years ago. During both these centuries, knowledge on symptomatology, pathophysiology, genetics and pharmaceutical and surgical treatment has significantly increased; however, this nosological entity continues to be of imprecise origin and progressive evolution. In the present review, the historical events that contributed to describe and improve the understanding of this disease are summarized. Read More

View Article
January 2018

Long-term treatment effect in cerebrotendinous xanthomatosis depends on age at treatment start.

Neurology 2018 Dec 7. Epub 2018 Dec 7.

From the Department of Neurology (B.M.L.S.), Catharina Hospital, Eindhoven; Department of Neurology (B.M.L.S., A.V.), Canisius Wilhelmina Hospital, Nijmegen; Department of Pediatrics (H.H.H.), Center for Lysosomal and Metabolic Diseases, Erasmus Medical Center-University Hospital, Rotterdam; Department of Neurology (B.P.C.v.d.W.), Donders Institute for Brain, Cognition and Behaviour (B.P.C.v.d.W., R.A.W.), and Department of Laboratory Medicine (L.A.J.K., R.A.W.), Translational Metabolic Laboratory, Radboud University Medical Center, Nijmegen; Department of Genetics (E.H.B.), University Medical Center Utrecht; Department of Internal Medicine (C.E.M.H.), Division of Endocrinology and Metabolism, Academic Medical Center, Amsterdam; Department of Internal Medicine (H.R.H.), Máxima Medical Center Eindhoven; Department of Internal Medicine (H.R.H.), Maastricht University Medical Center; and CAPHRI School for Public Health and Primary Care, Ageing and Long-Term Care (H.R.H.), Maastricht University, the Netherlands.

Objective: To evaluate the effect of chenodeoxycholic acid treatment on disease progression in cerebrotendinous xanthomatosis (CTX).

Methods: In this retrospective cohort study, we report the clinical long-term follow-up characteristics of 56 Dutch patients with CTX. Age at diagnosis was correlated with clinical characteristics and with the course of modified Rankin Scale (mRS) and Expanded Disability Status Scale (EDSS) scores at follow-up. Read More

View Article
December 2018

Tau imaging detects distinctive distribution of tau pathology in ALS/PDC on the Kii Peninsula.

Neurology 2018 Dec 7. Epub 2018 Dec 7.

From the Departments of Functional Brain Imaging Research (H. Shinotoh, H. Shimada, K.T., S.K., M.O., Y. Kimura, S.H., M.I., N.S., T.S., M.H.) and Radiopharmaceuticals Development (M.-R.Z.), National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba; Neurology Clinic Chiba (H. Shinotoh); Kii ALS/PDC Research Center (Y. Kokubo), Mie University; Department of Neurology and Gerontology (F.N.), Graduate School of Medical Science, Kyoto Prefectural University of Medicine; Department of Psychiatry (S.K.), Nara Medical University; Division of Neurology (H.E.), Kobe University Graduate School of Medicine, Hyogo; Center for Development of Advanced Medicine for Dementia, Department of Neurology (Y. Kimura), National Institute for Geriatrics and Gerontology, Aichi; Department of Neurology (S.H.), Chiba University; and Department of Neuropathology (M.M.), Institute for Medical Science of Aging, Aichi Medical University, Japan.

Objective: To characterize the distribution of tau pathology in patients with amyotrophic lateral sclerosis/parkinsonism dementia complex on the Kii Peninsula (Kii ALS/PDC) by tau PET using [C]PBB3 as ligand.

Methods: This is a cross-sectional study of 5 patients with ALS/PDC and one asymptomatic participant with a dense family history of ALS/PDC from the Kii Peninsula who took part in this study. All were men, and their age was 76 ± 8 (mean ± SD) years. Read More

View Article
December 2018

inPentasomes: An innovative nose-to-brain pentamidine delivery blunts MPTP parkinsonism in mice.

J Control Release 2018 Dec 7;294:17-26. Epub 2018 Dec 7.

Department of Drug Chemistry and Technology, Sapienza University of Rome, Rome, Italy.

Preclinical and clinical evidences have demonstrated that astroglial-derived S100B protein is a key element in neuroinflammation underlying the pathogenesis of Parkinson's disease (PD), so much as that S100B inhibitors have been proposed as promising candidates for PD targeted therapy. Pentamidine, an old-developed antiprotozoal drug, currently used for pneumocystis carinii is one of the most potent inhibitors of S100B activity, but despite this effect, is limited by its low capability to cross blood brain barrier (BBB). To overcome this problem, we developed a non-invasive intranasal delivery system, chitosan coated niosomes with entrapped pentamidine (inPentasomes), in the attempt to provide a novel pharmacological approach to ameliorate parkinsonism induced by subchronic MPTP administration in C57BL-6 J mice. Read More

View Article
December 2018

Bone loss in MPTP mouse model of Parkinson's disease is triggered by decreased osteoblastogenesis and increased osteoclastogenesis.

Toxicol Appl Pharmacol 2018 Dec 5;363:154-163. Epub 2018 Dec 5.

Department of Molecular Nutrition, CSIR-Central Food Technological Research Institute, Mysuru, India; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad 201002, India. Electronic address:

Bone loss is a non-motor symptom of Parkinson's disease (PD). It is unclear whether a patient's immobility or the endocrine changes in the body causes bone deterioration. To address this issue, we used an animal model of the disease where Swiss albino mice were injected with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on day 1 and were left untreated for eight weeks. Read More

View Article
December 2018

Clinical and genetic characteristics of late-onset Huntington's disease.

Parkinsonism Relat Disord 2018 Nov 29. Epub 2018 Nov 29.

Department of Clinical Genetics, Maastricht University Medical Center, Maastricht, the Netherlands; GROW Research Institute for Oncology and Developmental Biology, Maastricht University, Maastricht, the Netherlands.

Background: The frequency of late-onset Huntington's disease (>59 years) is assumed to be low and the clinical course milder. However, previous literature on late-onset disease is scarce and inconclusive.

Objective: Our aim is to study clinical characteristics of late-onset compared to common-onset HD patients in a large cohort of HD patients from the Registry database. Read More

View Article
November 2018
1 Read

Sphingolipids in the Pathogenesis of Parkinson's Disease and Parkinsonism.

Trends Endocrinol Metab 2018 Dec 6. Epub 2018 Dec 6.

Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA; Jan and Dan Duncan Neurological Research Institute, Texas Children's Hospital, Houston, TX 77030, USA; Program in Developmental Biology, Baylor College of Medicine, Houston, TX 77030, USA; Howard Hughes Medical Institute, Baylor College of Medicine, Houston, TX 77030, USA. Electronic address:

The pathogenic mechanisms underlying Parkinson's disease (PD)/parkinsonism affect mitochondrial and endolysosomal trafficking. The retromer is required to retrieve some proteins from endosomes to the Golgi and plasma membrane. Here, we discuss how retromer-dependent retrieval also affects ceramide metabolism. Read More

View Article
December 2018

Neuroimaging, genetic, and enzymatic study in a Japanese family with a GBA gross deletion.

Parkinsonism Relat Disord 2018 Dec 2. Epub 2018 Dec 2.

Department of Neurology, Graduate School of Medical Sciences, University of Yamanashi, Yamanashi, Japan. Electronic address:

Introduction: Glucocerebrosidase gene (GBA) variants are associated with Parkinson's disease (PD) and dementia with Lewy bodies (DLB). The molecular mechanisms underlying these diseases with GBA variants, however, are not well understood. In order to determine the effect of a deletion mutation in GBA, we performed a neuroimaging, genetic, and enzymatic study in a Japanese family with a gross deletion of exons 3 to 11 in GBA. Read More

View Article
December 2018

Setting the record straight: The nosology of tardive syndromes.

Parkinsonism Relat Disord 2018 Nov 28. Epub 2018 Nov 28.

Department of Neurology, Loma Linda University Medical Center, Loma Linda, CA, USA.

We propose the use of the term tardive dyskinesia to refer to the original description of repetitive and complex oral-buccal-lingual (OBL) movements and the analogous repetitive movements of the limbs, trunk, or pelvis. The term tardive syndrome is an umbrella term to be used to refer to the spectrum of all persistent hyperkinetic, hypokinetic, and sensory phenomenologies resulting from chronic dopamine receptor blocking agent (DRBA) exposure. TD is a type of TS. Read More

View Article
November 2018
1 Read

Thalamic and ventricular volumes predict motor response to deep brain stimulation for Parkinson's disease.

Parkinsonism Relat Disord 2018 Nov 28. Epub 2018 Nov 28.

Department of Neurology, Washington University in St Louis, 660 S Euclid Ave, Campus Box 8111, St Louis, MO, 63110, USA; Department of Radiology, Washington University in St. Louis, 660 S. Euclid Ave, Campus Box 8225, St. Louis, MO, 63110, USA. Electronic address:

Background: Brain atrophy frequently occurs with Parkinson's disease (PD) and relates to increased motor symptoms of PD. The predictive value of neuroimaging-based measures of global and regional brain volume on motor outcomes in deep brain stimulation (DBS) remains unclear but potentially could improve patient selection and targeting.

Objectives: To determine the predictive value of preoperative volumetric MRI measures of cortical and subcortical brain volume on motor outcomes of subthalamic nucleus (STN) DBS in PD. Read More

View Article
November 2018

Multiparametric MR imaging of Parkinsonisms at 3 tesla: Its role in the differentiation of idiopathic Parkinson's disease versus atypical Parkinsonian disorders.

Eur J Radiol 2018 Dec 1;109:95-100. Epub 2018 Nov 1.

Neuroradiology Unit, Ospedale Maggiore Policlinico IRCCS Ca' Granda, Milan, Italy.

Objectives: The Nigrosome-1 and putaminal hypointensity depicted on susceptibility-weighted imaging (SWI), and midbrain atrophy assessed on T1-weighted are some of the most common radiological parameters to diagnose Parkinsonism at Magnetic Resonance (MR) imaging. Our aim is to assess the feasibility of these signs in the differentiation of Idiopathic Parkinson's disease (IPD) patients versus disease (DC) and healthy controls (HC) and in the assessment of the Atypical Progressive Parkinsonisms (APPs).

Methods: Presence or loss of the Nigrosome-1 was assessed retrospectively on multiple-echo SWI obtained on a 3 T scan by two neuroradiologists. Read More

View Article
December 2018

Association between use of antiemetics, antipsychotics, or antidepressants and the risk of Parkinson's disease
.

Int J Clin Pharmacol Ther 2018 Dec 11. Epub 2018 Dec 11.

Objective: Antipsychotics, antidepressants, and antiemetics are well-known causative agents of parkinsonism. However, it is not certain that the use of these medications increases the risk of Parkinson's disease (PD). We aim to define the risk of PD associated with use of antipsychotic, antidepressant, or antiemetic therapy. Read More

View Article
December 2018

Corrigendum: Validation of a Questionnaire for Distinguishing X-Linked Dystonia Parkinsonism From Its Mimics.

Front Neurol 2018 20;9:991. Epub 2018 Nov 20.

Department of Neurosciences, College of Medicine and Philippine General Hospital, University of the Philippines Manila, Manila, Philippines.

[This corrects the article DOI: 10.3389/fneur.2018. Read More

View Article
November 2018
1 Read

Modeling Parkinson's Disease and Atypical Parkinsonian Syndromes Using Induced Pluripotent Stem Cells.

Int J Mol Sci 2018 Dec 4;19(12). Epub 2018 Dec 4.

Department of Neurology, Fukuoka University, Fukuoka 814-0180, Japan.

Parkinson's disease (PD) and atypical parkinsonian syndromes are age-dependent multifactorial neurodegenerative diseases, which are clinically characterized by bradykinesia, tremor, muscle rigidity and postural instability. Although these diseases share several common clinical phenotypes, their pathophysiological aspects vary among the disease categories. Extensive animal-based approaches, as well as postmortem studies, have provided important insights into the disease mechanisms and potential therapeutic targets. Read More

View Article
December 2018
8 Reads

Association of Pallidal Neurostimulation and Outcome Predictors With X-linked Dystonia Parkinsonism.

JAMA Neurol 2018 Dec 3. Epub 2018 Dec 3.

Institute of Neurogenetics, University of Lübeck, Lübeck, Germany.

Importance: Anecdotal evidence suggests that deep brain stimulation (DBS) of the internal globus pallidus (GPi) is effective in ameliorating dystonia in X-linked dystonia parkinsonism (XDP), a disease that is usually refractive to medical therapy.

Objective: To determine the efficacy of GPi-DBS in a cohort of patients with XDP in a prospective study and identify predictors of postoperative outcomes.

Design, Setting, And Participants: This observational prospective cohort study enrolled patients in February 2013 and was completed in December 2014. Read More

View Article
December 2018
1 Read

Association of Cerebrospinal Fluid Neurofilament Light Protein Levels With Cognition in Patients With Dementia, Motor Neuron Disease, and Movement Disorders.

JAMA Neurol 2018 Dec 3. Epub 2018 Dec 3.

Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy, University of Gothenburg, Mölndal, Sweden.

Importance: Neuronal and axonal destruction are hallmarks of neurodegenerative diseases, but it is difficult to estimate the extent and progress of the damage in the disease process.

Objective: To investigate cerebrospinal fluid (CSF) levels of neurofilament light (NFL) protein, a marker of neuroaxonal degeneration, in control participants and patients with dementia, motor neuron disease, and parkinsonian disorders (determined by clinical criteria and autopsy), and determine its association with longitudinal cognitive decline.

Design, Setting, And Participants: In this case-control study, we investigated NFL levels in CSF obtained from controls and patients with several neurodegenerative diseases. Read More

View Article
December 2018
1 Read

Intrapallidal injection of botulinum toxin A recovers gait deficits in a parkinsonian rodent model.

Acta Physiol (Oxf) 2018 Dec 3:e13230. Epub 2018 Dec 3.

Department of Physiology and Pharmacology, Western University, London, Ontario, Canada.

Aim: Modulation of electrical activity in the subthalamic nucleus has been therapeutically effective in Parkinson's disease. Pharmacological manipulation of glutamate release from subthalamic neurons could also favourably alter basal ganglia activity to improve motor symptoms. The present study investigates the efficacy of selective suppression of hyperactive glutamatergic input from the subthalamic nucleus to the globus pallidus internal segment by botulinum toxin A (BoNT-A) in a parkinsonian model. Read More

View Article
December 2018
1 Read

c-Abl Inhibition Exerts Symptomatic Antiparkinsonian Effects Through a Striatal Postsynaptic Mechanism.

Front Pharmacol 2018 16;9:1311. Epub 2018 Nov 16.

Department of Neurodegenerative Disorders Research, Institute of Biomedical Sciences, Graduate School of Medical Sciences, Tokushima University, Tokushima, Japan.

Parkinson's disease (PD) is caused by a progressive degeneration of nigral dopaminergic cells leading to striatal dopamine deficiency. From the perspective of antiparkinsonian drug mechanisms, pharmacologic treatment of PD can be divided into symptomatic and disease-modifying (neuroprotective) therapies. An increase in the level and activity of the Abelson non-receptor tyrosine kinase (c-Abl) has been identified in both human and mouse brains under PD conditions. Read More

View Article
November 2018

A phase IIb, randomised, double-blind, placebo-controlled, dose-ranging investigation of the safety and efficacy of NTCELL [immunoprotected (alginate-encapsulated) porcine choroid plexus cells for xenotransplantation] in patients with Parkinson's disease.

Parkinsonism Relat Disord 2018 Nov 13. Epub 2018 Nov 13.

Department of Neurology, Auckland City Hospital, 2 Park Road, Grafton, Auckland, 1023, New Zealand; Centre for Brain Research, University of Auckland, New Zealand. Electronic address:

Introduction: Regenerative therapies in Parkinson's disease aim to slow neurodegeneration and re-establish damaged neuronal circuitry. Neurotrophins are potent endogenous regulators of neuronal survival, development and regeneration. They represent an attractive regenerative treatment option in Parkinson's disease. Read More

View Article
November 2018
1 Read

Quantification of brain-derived extracellular vesicles in plasma as a biomarker to diagnose Parkinson's and related diseases.

Parkinsonism Relat Disord 2018 Nov 20. Epub 2018 Nov 20.

Department of Neurology, Kyoto Prefectural University of Medicine, Kyoto, 602-0841, Japan; Department of Molecular Pathobiology of Brain Diseases, Kyoto Prefectural University of Medicine, Kyoto, 602-0841, Japan. Electronic address:

Introduction: There is still a substantial unmet need for blood-based biomarkers to make an objective diagnosis of Parkinson's disease (PD) and the parkinsonism-plus syndromes. This study is aimed to determine whether enumeration of brain-derived exosomes (BDEs) in plasma is informative in the diagnosis of those diseases.

Methods: We have developed a specific method to enumerate the plasma levels of neuron-derived, astrocyte-derived, and oligodendrocyte-derived exosomes (NDEs, ADEs and ODEs, respectively), and quantified them individually in patients with PD (n = 15), multiple system atrophy (MSA, n = 15), progressive supranuclear palsy (PSP, n = 7) and disease controls (n = 15). Read More

View Article
November 2018
1 Read

Exploring bedside clinical features of parkinsonism: A focus on differential diagnosis.

Parkinsonism Relat Disord 2018 Nov 5. Epub 2018 Nov 5.

Center for Neurological Restoration, Cleveland Clinic, Cleveland, OH, USA.

The proper diagnosis of parkinsonian disorders usually involves three steps: identifying core features of parkinsonism; excluding other causes; and collating supportive evidence based on clinical signs or investigations. While the recognition of cardinal parkinsonian features is usually straightforward, the appreciation of clinical features suggestive of specific parkinsonian disorders can be challenging, and often requires greater experience and skills. In this review, we outline the clinical features that are relevant to the differential diagnosis of common neurodegenerative parkinsonian disorders, including Parkinson's disease, multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration. Read More

View Article
November 2018
2 Reads

Neurologic conditions and disorders of uremic syndrome of chronic kidney disease: Presentations, causes and treatment strategies.

Authors:
Sherifa A Hamed

Expert Rev Clin Pharmacol 2018 Dec 2. Epub 2018 Dec 2.

a Department of Neurology and Psychiatry , Assiut University Hospital , Assiut , Egypt.

Introduction: Uremic syndrome of chronic kidney disease (CKD) is a term used to describe clinical, metabolic and hormonal abnormalities associated with progressive kidney failure. It is a rapidly growing public health problem worldwide. Nervous system complications occur in every patient with uremic syndrome of CKD. Read More

View Article
December 2018
1 Read

Computational Investigation of RNA A-Bulges Related to Microtubule-Associated Protein Tau Causing Frontotemporal Dementia and Parkinsonism.

J Phys Chem B 2018 Dec 5. Epub 2018 Dec 5.

Mutations in the human tau gene result in alternative splicing of the tau protein, which cause frontotemporal dementia and Parkinsonism. One disease mechanism is linked to the stability of a hairpin within microtubule-associated protein tau (MAPT) mRNA, which contains an A-bulge. Here we employ computational methods to investigate the structural and thermodynamic properties of several A-bulge RNAs with different closing base-pairs. Read More

View Article
December 2018
2 Reads

Bilateral Basal Ganglia Necrosis Secondary to Methamphetamine.

Mov Disord Clin Pract 2018 Sep-Oct;5(5):555-556. Epub 2018 Aug 2.

Department of Neurology University of Florida College of Medicine Gainesville Florida USA.

View Article

Medical decision-making in progressive supranuclear palsy: A comparison to other neurodegenerative disorders.

Parkinsonism Relat Disord 2018 Nov 26. Epub 2018 Nov 26.

Department of Neurology, University of Alabama at Birmingham, Birmingham, AL, USA; Alzheimer's Disease Center, University of Alabama at Birmingham, Birmingham, AL, USA; Evelyn F. McKnight Brain Institute, University of Alabama at Birmingham, Birmingham, AL, USA; Center for Neurodegeneration and Experimental Therapeutics, University of Alabama at Birmingham, Birmingham, AL, USA.

Introduction: Cognitive dysfunction is common in progressive supranuclear palsy (PSP) but its effect on medical decision-making has not been well studied. To address this gap in the research literature, we compared the medical decision-making capacity of patients with PSP to groups of patients with other neurodegenerative disorders. We also investigated the cognitive correlates of medical decision-making in our PSP sample. Read More

View Article
November 2018
4 Reads

Successful pallidotomy for post-hyperglycemic hemichorea-ballism.

Parkinsonism Relat Disord 2018 Nov 28. Epub 2018 Nov 28.

Division of Neurosurgery, Toronto Western Hospital, University Health Network, 399 Bathurst Street, Toronto, M5T 2S8, Ontario, Canada. Electronic address:

View Article
November 2018
1 Read
3.972 Impact Factor

Stridor-related gray matter alterations in multiple system atrophy: A pilot study.

Parkinsonism Relat Disord 2018 Nov 17. Epub 2018 Nov 17.

Department of Biomedical and NeuroMotor Sciences, University of Bologna, Bologna, Italy; IRCCS Istituto delle Scienze Neurologiche di Bologna, Clinica Neurologica, Bologna, Italy.

Introduction: The neuroanatomical substrate of stridor associated with Multiple System Atrophy (MSA) remains unclear. We evaluated stridor-related gray matter (GM) changes in MSA.

Methods: 36 MSA patients underwent standardized nocturnal video-polysomnography and brain MRI. Read More

View Article
November 2018
5 Reads

MIND Diet Associated with Reduced Incidence and Delayed Progression of ParkinsonismA in Old Age.

J Nutr Health Aging 2018 ;22(10):1211-1215

Puja Agarwal, Rush University Medical Center, 1645 W Jackson, Chicago, IL, 60612, Phone: 312-563-0151,

Background: In old age, motor impairments including parkinsonian signs are common, but treatment is lacking for many older adults. In this study, we examined the association of a diet specifically developed to promote brain health, called MIND (Mediterranean-DASH Diet Intervention for Neurodegenerative Delay), to the incidence and progression of parkinsonism in older adults.

Methods: A total of 706 Memory and Aging Project participants aged 59 -97 years and without parkinsonism at baseline were assessed annually for the presence of four parkinsonian signs using a 26-item modified version of the United Parkinson's Disease Rating Scale. Read More

View Article
January 2018
1 Read

Time to onset and time to resolution of extrapyramidal symptoms in patients with exacerbated schizophrenia treated with 3-monthly vs once-monthly paliperidone palmitate.

Neuropsychiatr Dis Treat 2018 25;14:2807-2816. Epub 2018 Oct 25.

Janssen Research and Development, LLC, Titusville, NJ, USA,

Objective: The aim of this study was to evaluate the safety of 3-monthly paliperidone palmitate (PP3M) vs once-monthly paliperidone palmitate (PP1M) treatment with regard to extrapyramidal symptom (EPS)-related treatment-emergent adverse events (TEAEs) in patients with schizophrenia, previously stabilized on PP1M treatment.

Patients And Methods: Data on overall incidence, time to onset (TTO), and time to resolution (TTR) of EPS-related TEAEs (overall, subclasses such as dyskinesia, dystonia, hyperkinesia, parkinsonism, and tremor) from a randomized double-blind (DB) non-inferiority study were compared between PP3M and PP1M. Subgroup analysis was performed by age (18-25, 26-50, and 50+ years) and final open-label (OL) dose (50/75, 100, and 150 mg eq. Read More

View Article
October 2018
1 Read

Effect of unilateral subthalamic deep brain stimulation in highly asymmetrical Parkinson's disease: 7-year follow-up.

Authors:

J Neurosurg 2018 Nov 1:1-6. Epub 2018 Nov 1.

OBJECTIVEFor patients with highly asymmetrical Parkinson's disease (PD), unilateral subthalamic nucleus (STN) deep brain stimulation (DBS) has been suggested as a reasonable treatment. However, the results of a previous 2-year follow-up study involving patients with prominently asymmetrical PD who had unilateral STN DBS suggested that simultaneous bilateral surgery should be performed. In the present study, the authors analyze 7-year follow-up data from the same patient group to examine changes in motor benefit from unilateral STN DBS over time and the interval between initial unilateral surgery and a second (contralateral) STN DBS surgery. Read More

View Article
November 2018

Ropinirole Augmentation for Depression: A Randomized Controlled Trial Pilot Study.

J Clin Psychopharmacol 2018 Nov 26. Epub 2018 Nov 26.

Jerusalem Mental Health Center, Jerusalem, Israel.

Objective: Evidence both from animal and human studies suggests a role for dopaminergic pathways in the treatment of depression. Ropinirole, a selective agonist of dopamine D2/D3, is in use for the treatment of parkinsonism. Preliminary evidence suggests that such agonists might be useful as antidepressants. Read More

View Article
November 2018
4 Reads